MX107

CAS No. 2170102-50-6

MX107( MX 107 )

Catalog No. M13464 CAS No. 2170102-50-6

MX107 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 3.1 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MX107
  • Note
    Research use only, not for human use.
  • Brief Description
    MX107 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 3.1 uM.
  • Description
    MX107 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 3.1 uM; significantly enhances the tumoricidal efficacy of doxorubicin in TNBC cells, induces degradation of XIAP and/or cIAP1, which inhibited NF-κB activation by genotoxic agents.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    MX 107
  • Pathway
    Apoptosis
  • Target
    IAP
  • Recptor
    IAP
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2170102-50-6
  • Formula Weight
    376.5
  • Molecular Formula
    C24H28N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC1=C2N=CC=CC2=C(COCC3=CC=C(CC)C=C3)C=C1CN4CCCC4
  • Chemical Name
    5-(((4-ethylbenzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wang W, et al. J Pharmacol Exp Ther. 2018 May 7. pii: jpet.118.249151.
molnova catalog
related products
  • SM-1295

    SM-1295 is a potent, selective cIAP1 and cIAP2 inhibitor with Ki of <10 nM, displays >900-fold for cIAP1 over XIAP.

  • YM-155 hydrochloride

    A potent, specific survivin inhibitor that inhibits survivin promoter activity with IC50 of 0.54 nM.

  • Birinapant

    Birinapant is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM, less potent to XIAP. Phase 2.